-
Semin Cutan Med Surg · Jun 2014
ReviewCurrent status and future directions of molecularly targeted therapies and immunotherapies for melanoma.
- David M Miller, Keith T Flaherty, and Hensin Tsao.
- Wellman Center for Photomedicine and Department of Dermatology, MGH Cancer Center, Massachusetts General Hospital, MA USA. E-mail: htsao@partners.org.
- Semin Cutan Med Surg. 2014 Jun 1; 33 (2): 60-7.
AbstractKey molecular and immunological insights over the past decade have radically changed the face of therapy in melanoma. Whereas 5 years ago, treatment for advanced melanoma was restricted to the alkylating agent dacarbazine and the immunostimulants interleukin-2 and interferon-α-2b, today the therapeutic menu includes precise therapies that target key determinants in oncogenic pathways and immune checkpoints. In this chapter, we will review the current status and future directions of targeted therapies for melanoma directed at mitogen-activated pathways and immune checkpoints.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*,_underline_or**bold**. - Superscript can be denoted by
<sup>text</sup>and subscript<sub>text</sub>. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3., hyphens-or asterisks*. - Links can be included with:
[my link to pubmed](http://pubmed.com) - Images can be included with:
 - For footnotes use
[^1](This is a footnote.)inline. - Or use an inline reference
[^1]to refer to a longer footnote elseweher in the document[^1]: This is a long footnote..